US6041253A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Effect of electric field and ultrasound for transdermal drug delivery
Assignee: Massachusetts Institute of Technology
•
Filing: 1996-04-01
•
Granted: 2000-03-21
•
Expires: 2016-04-01
Abstract
Abstract Transdermal transport of molecules during sonophoresis (delivery or extraction) can be further enhanced by application of an electric field, for example, electroporation or iontophoresis. In a preferred embodiment the ultrasound is low frequency ultrasound which induces cavitation of the lipid layers of the stratum corneum (SC). This method provides higher drug transdermal fluxes, allows rapid control of transdermal fluxes, and allows drug delivery or analyte extraction at lower ultrasound intensities than when ultrasound is applied in the absence of an electric field.
Inventors
- 👤 Joseph Kost
- 👤 Uwe Pliquett
- 👤 Samir S. Mitragotri
- 👤 Robert S. Langer
- 👤 James C. Weaver
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 23:39
CPC Classifications
A; A61; A61N; A61N1/00; A61N1/18; A61N1/32; A61N1/325; A61B; A61B5/00; A61B5/145; A61B5/14507; A61B5/1451; A61B5/14514; A61K; A61K41/00; A61K41/0047; A61K9/00; A61K9/0002; A61K9/0009; A61M; A61M37/00; A61M37/0092; A61N1/02; A61N1/04; A61N1/0404; A61N1/0408; A61N1/0412; A61N1/327; A61M2037/0007; A61N1/0416; A61N1/042; A61N1/0428
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
45 words
A method for enhancing transdermal transport of compounds comprising administering to the skin an effective amount of ultrasound at a frequency of less than 2.5 MHz to permeabilize the skin followed by an enhancer selected from the group consisting of electroporation, vacuum or mechanical pressure.
Claim 2
Independent Claim
45 words
A method for enhancing transdermal transport of compounds comprising administering to the skin an effective amount of ultrasound at a frequency of less than 2.5 MHz to permeabilize the skin followed by an enhancer selected from the group consisting of electroporation, vacuum or mechanical pressure.
Claim 3
Dependent Claim
49 words
The method of claim 1 comprising administering to the skin an effective amount of ultrasound at a frequency of less than 2.5 MHz in combination with electroporation at a voltage of between about 20 V and about 150 V followed by the application of a vacuum or mechanical pressure.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein the ultrasound is administered at a frequency of 1 MHz or less.
Claim 5
Dependent Claim
24 words
The method of claim 1 wherein the intensity of the ultrasound is less than the maximum intensity that will not cause permanent skin damage.
Claim 6
Dependent Claim
18 words
The method of claim 1 wherein the intensity of the ultrasound is less than 2.5 W/cm 2 .
Claim 7
Dependent Claim
30 words
The method of claim 1 comprising administering to the skin an effective amount of ultrasound at a frequency of less than 2.5 MHz followed by electroporation to effect transdermal transport.
Claim 8
Dependent Claim
17 words
The method of claim 1 wherein the ultrasound is followed by administration of vacuumn or mechanical pressure.
Claim 9
Dependent Claim
20 words
The method of claim 1 wherein the compound to be transported is a drug the patient is in need of.
Claim 10
Dependent Claim
17 words
The method of claim 1 wherein the compound to be transported is an analyte to be measured.
Claim 11
Dependent Claim
10 words
The method of claim 1 wherein the ultrasound is pulsed.
References Cited (Backward Citations)
US3551554A
Cited
US3711606A
Cited
US3711602A
Cited
US4002221A
Cited
SU445433A1
Cited
SU506421A1
Cited
US4144646A
Cited
US4127125A
Cited
SU556805A1
Cited
US4309989A
Cited
GB1577551A
Cited
SU591186A1
Cited
DE2756460A1
Cited
US4176664A
Cited
US4280494A
Cited
US4249531A
Cited
SU910157A1
Cited
EP0043738B1
Cited
US4372296A
Cited
US4537776A
Cited
US4563184A
Cited
US4557943A
Cited
US4646725A
Cited
GB2153223A
Cited
US4595011A
Cited
US4732153A
Cited
US4834978A
Cited
US4698058A
Cited
WO1988000001A2
Cited
US4767402A
Cited
US4863970A
Cited
US4855298A
Cited
US4821740A
Cited
US4953565A
Cited
US5007438A
Cited
US5006342A
Cited
US4860058A
Cited
US4787888A
Cited
US4780212A
Cited
US4821733A
Cited
US4820720A
Cited
US5019034B1
Cited
US5019034A
Cited
US5015615A
Cited
WO1990001971A1
Cited
US5076273A
Cited
EP0368408A2
Cited
US5139023A
Cited
WO1990015568A2
Cited
JPH03170172A
Cited
US5140985A
Cited
US5115805A
Cited
WO1991012772A1
Cited
US5231975A
Cited
US5323769A
Cited
US5197946A
Cited
US5315998A
Cited
US5401237A
Cited
US5171215A
Cited
US5405614A
Cited
WO1993020745A1
Cited
US5582586A
Cited
US5421816A
Cited
US5617851A
Cited
US5386837A
Cited
US5267985A
Cited
EP0612525A1
Cited
US5658247A
Cited
US5415629A
Cited
US5458140A
Cited
US5445611A
Cited
US5443080A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-03-21 | 2003-09-20 | 2004-03-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-03-21 | 2007-09-20 | 2008-03-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-03-21 | 2011-09-20 | 2012-03-21 | $7700.00 | Window Closed / Lapsed |